Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2014; 111(05): 781-782
DOI: 10.1160/TH14-03-0228
DOI: 10.1160/TH14-03-0228
Editorial
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
Authors
Further Information
Publication History
Received:
10 March 2014
Accepted:
13 March 2014
Publication Date:
01 December 2017 (online)
Note: The editorial process for this paper was fully handled by Prof Christian Weber, Editor in Chief.
-
References
- 1 Gallego P, Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
- 2 De Caterina R, Husted S, Wallentin L. et al. Vitamin k antagonists in heart disease: Current status, perspectives (section iii). Position paper of the esc working group on thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: 1087-1107.
- 3 De Caterina R, Husted S, Wallentin L. et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: Esc working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012; 59: 1413-1425.
- 4 Ogilvie IM, Newton N, Welner SA. et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638-645. e634.
- 5 Wilke T, Groth A, Mueller S. et al. Oral anticoagulation use by patients with atrial fibrillation in germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
- 6 De Caterina R, Husted S, Wallentin L. et al. General mechanisms of coagulation, targets of anticoagulants (section i). Position paper of the esc working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 569-579.
- 7 Weitz JI, Eikelboom JW, Samama MM. New anti-thrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e120S-151S.
- 8 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace 2012; 14: 1385-1413.
- 9 Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 2013; 26: 191-202.
- 10 Heidbuchel H, Verhamme P, Alings M. et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
- 11 Lip GYH, Camm AJ, Hylek EM. et al. Non-Vitamin K Antagonist Oral Anticoagulants: An Appeal for Consensus on Terminology. Chest. 2014 Epub ahead of print
- 12 De Caterina R, Husted S, Wallentin L. et al. Parenteral anticoagulants in heart disease: Current status, perspectives (section ii). Position paper of the esc working group on thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 769-786.